• Analysts' EPS Estimates: Wall Street analysts estimate an EPS of $0.24.
• Revenue Growth: Projected quarterly revenue of $120.13 million, a 12.5% increase from the previous year, signaling positive growth for Phreesia.

Phreesia, Inc. (NYSE:PHR) is a healthcare technology company that provides a patient intake and engagement platform. The company helps healthcare organizations manage patient intake, improve patient engagement, and optimize revenue cycle management. As PHR prepares to release its quarterly earnings on December 8, 2025, Wall Street analysts are estimating an earnings per share (EPS) of $0.24 and revenue of approximately $120 million.

Phreesia's projected revenue for the quarter is $120.13 million, reflecting a 12.5% increase compared to the same quarter last year. This growth in revenue is a positive indicator for the company, as higher revenues are expected to drive the year-over-year increase in earnings. Investors are keenly watching to see if Phreesia will surpass these expectations, as an earnings beat could positively impact its stock price.

Phreesia's price-to-sales ratio of 2.72 suggests that investors are willing to pay $2.72 for every dollar of sales. The enterprise value to sales ratio of 2.51 indicates a relatively efficient use of capital. Additionally, the company's low debt-to-equity ratio of 0.016 suggests minimal reliance on debt financing, while a current ratio of 2.12 indicates a strong ability to cover short-term liabilities.

The upcoming earnings report and management's discussion during the earnings call will be crucial in determining the sustainability of any immediate price changes and future earnings expectations. Investors rely on consensus earnings and revenue estimates to gauge potential stock performance, and the outcome of Phreesia's earnings report could lead to a stock price increase if results exceed estimates. Conversely, a miss could result in a decline.